

Table S1. Characteristics of patients with and without 9 months of continuous warfarin use following initial prescription

| | Patients with at least 9 months of continuous warfarin | Patients without 9 months of continuous warfarin | |
|-------------------------------|--|--|----------------------|
| | | | |
| | | | |
| | use | use | |
| Variable* | N (%) | N (%) | P value [†] |
| All | 2928 (100%) | 1532 (100%) | |
| Age | | | 0.60 |
| ≥75 years | 1264 (43.2%) | 656 (42.8%) | |
| Sex | | | 0.022 |
| Women | 1272 (43.4%) | 611 (39.9%) | |
| Race | | | 0.002 |
| White | 2555 (87.3%) | 1291 (84.3%) | |
| Diabetes mellitus | | | 0.87 |
| Yes | 480 (16.4%) | 254 (16.6%) | |
| Hypertension | | | 0.089 |
| Yes | 1611 (55.0%) | 802 (52.3%) | |
| Coronary artery disease | | | 0.60 |
| Yes | 813 (27.8%) | 414 (27.0%) | |
| Heart failure | | | 0.79 |
| Yes | 779 (26.6%) | 402 (26.2%) | |
| Peripheral artery disease | | | 0.62 |
| Yes | 74 (2.5%) | 35 (2.3%) | |
| Renal impairment [‡] | | | 0.72 |

| | Patients with at least 9 months of continuous warfarin | Patients without 9 months of continuous warfarin | |
|---|--|--|----------------------|
| | | | |
| | | | |
| | use | use | |
| Variable* | N (%) | N (%) | P value [†] |
| Yes | 360 (12.3%) | 194 (12.7%) | |
| Prior stroke | | | 0.020 |
| Yes | 279 (9.5%) | 114 (7.4%) | |
| Cancer | | | 0.012 |
| Yes | 342 (11.7%) | 219 (14.3%) | |
| Prior bleed | | | 0.019 |
| Yes | 162 (5.5%) | 112 (7.3%) | |
| Beta blockers | | | 0.79 |
| Yes | 969 (33.1%) | 513 (33.5%) | |
| Anti-arrhythmics | | | 0.073 |
| Yes | 484 (16.5%) | 286 (18.7%) | |
| Calcium channel blockers | | | 0.68 |
| Yes | 764 (26.1%) | 391 (25.5%) | |
| ATRIA score at admission§ | | | 0.18 |
| 0-5 | 1500 (51.2%) | 824 (53.8%) | |
| 6 | 418 (14.3%) | 200 (13.1%) | |
| ≥7 | 1010 (34.5%) | 508 (33.2%) | |
| CHA ₂ DS ₂ -VASc score at | | | 0.001 |
| admission | | | |

168 (5.7%)

0

134 (8.7%)

Patients with at least

Patients without 9

9 months of

months of

continuous warfarin

continuous warfarin

use

use

| Variable* | N (%) | N (%) | P value [†] |
|-----------|--------------|--------------|----------------------|
| 1 | 457 (15.6%) | 265 (17.3%) | |
| ≥2 | 2303 (78.7%) | 1133 (74.0%) | |

^{*}Variables assessed at the beginning of the 15-month follow-up period.

[†]Univariate p values from chi-square tests.

[‡]Estimated glomerular filtration rate <45 ml/min/1.73m² or end stage renal disease.

[§] ATRIA risk score includes prior stroke, age, sex, diabetes, congestive heart failure, hypertension, proteinuria, and eGFR<45 or ESRD.³⁶

 $^{^{\}parallel}$ CHA $_{2}$ DS $_{2}$ VASc score includes congestive heart failure, hypertension, age, diabetes mellitus, stroke/TIA/thromboembolism, vascular disease, and sex. 37